NCT07400523 2026-04-17
Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Recruiting
Clinical Trials
15 trialsNCT07222267 2026-04-15
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT05879926 2026-04-02
OFSET
NRG Oncology
Phase 3 Recruiting
NCT06218303 2026-03-12
Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ
University of Pittsburgh
Phase 1 Recruiting
NCT03624244 2026-02-17
BFR-ESS
Centre Leon Berard
Phase 2 Recruiting
NCT06534125 2026-01-29
Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer
Emory University
Phase NA Recruiting
NCT06970912 2026-01-21
DNADalHR
Peking University People's Hospital
Phase 2 Recruiting
NCT06107673 2025-12-11
Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）
Hebei Medical University Fourth Hospital
Phase 2 Recruiting
NCT06361940 2025-10-14
MAPPER
Medical College of Wisconsin
Phase 2 Recruiting
NCT05362760 2025-05-16
MINERVA
University of Ulm
Phase 4 Recruiting
NCT05190094 2025-05-07
ICRG0201
International Cancer Research Group, United Arab Emirates
Phase 2 Recruiting
NCT05594095 2024-10-04
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
Fudan University
Phase 2 Recruiting
NCT06447623 2024-06-07
Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer
Fudan University
Phase 3 Recruiting
NCT05949541 2024-02-08
BCTOP-L-M01
Fudan University
Phase 2 Recruiting
NCT03621904 2023-01-18
PROMOTE
Radboud University Medical Center
Recruiting